A new vaccine, manufactured by hair product manufacture Tresemme, has been approved for use in the USA by the Food & Drug Administration and by 85% of 104 women questioned The vaccine, the first to include Guar Hydroxypropyltrimonium Chloride and DMDM Hydantoin, has been praised highly by hairdressers across the nation as ‘Probably preventing breathing difficulties whilst also stopping traffic fumes being absorbed into hair’.
New hair products typically take five to ten years of intensive R&D before release, but thanks to new processes introduced by Tresemme, including feeding researchers with Biotin and Hethylisothiazolinone, the research cycle was reduced to weeks. Whilst the FDA admitted that Tresemme was unable to provide any evidence that it prevented the user catching COVID-19, it said that the benefits of visibly thicker and fuller hair in just one use outweighed any non-clinical disadvantages, adding that ‘All those lovely ladies can’t be wrong’.
